Partner Headlines - TEVA

  1. Momenta Pharma

    IBD
  2. Momenta Downgraded After Stock Price Doubles

    IBD
  3. Teva-Xenon Arthritis Pain Drug Fails Midstage Trial

    IBD
  4. Wednesday's Mid-Day Movers: Chubb, Rock Creed, RADA Win; Peabody ...

    Benzinga
  5. Unusual Covered Call Opportunity Teva Pharmaceuticals

    Benzinga
  6. Alder Bio Up As Credit Suisse Lauds Migraine Drug

    IBD
  7. New America's IPO Stock Winners: Fitbit, Arista

    IBD
  8. ObamaCare Enables Health Insurer Merger Mania

    IBD
  9. Paul Tudor Jones Buys Stakes in ADP and Visa

    GuruFocus
  10. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  11. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  12. Teva to Present New Findings at the American Headache Society ...

    Benzinga
  13. How High Can Eagle Pharmaceuticals Fly On Teva Deal?

    IBD
  14. Teva's Mylan bid hits snag

    IBD
  15. Teva's Auspex Buyout Pays, But Mylan Bid Hits Snag

    IBD
  16. Teva Advances Pipeline of Movement Disorder Assets with Announcement ...

    Benzinga
  17. Top Biotech Stock Files For New Drug, In Buy Range

    IBD
  18. Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks

    GuruFocus
  19. New Migraine Drugs Could Ease Investors' Headaches

    IBD
  20. Benzinga's M&A Chatter for Tuesday June 9, 2015

    Benzinga
  21. Leon Cooperman's Top Holdings Look Attractive

    GuruFocus
  22. Teva Pharmaceuticals

    IBD
  23. 6-K from Teva Pharma Shows Letter from CEO Vigodman, Chair Peterburg ...

    Benzinga
  24. Mobileye Hangs Just Below Buy Point In Deep Cup Base

    IBD
  25. Perrigo buys Glaxo OTC drugs

    IBD
  26. Will Perrigo's Glaxo Buy Make It Too Pricey?

    IBD
  27. Mylan Sends Letter to Teva CEO

    Benzinga
  28. Teva Announces Exclusive Launch of Generic Actonel Tablets in ...

    Benzinga
  29. Teva to pay $1.2 bil to settle

    IBD
  30. Regeneron, Lannett Among The 4 Top-Rated Drug Stocks

    IBD
  31. Benzinga's M&A Chatter for Wednesday May 27, 2015

    Benzinga
  32. TEVA PHARMA

    IBD
  33. Actavis Stock - A Must Have For Long-Term Investors

    GuruFocus
  34. Big Pharma Companies Are Betting On Regenerative Medicine - Should ...

    GuruFocus
  35. Stanley Druckenmiller's Top 5 New Stocks

    GuruFocus
  36. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  37. Endo Buying Par Pharma To Become Top Generics Player

    IBD
  38. IPO Stock Watch: Alder Soars On Migraine Drug Results

    IBD
  39. U.S. Loves Europe As Pharma, Energy Boost M&A

    IBD
  40. Actavis Offers Post-Allergan Guidance; Ligand Jumps

    IBD
  41. Actavis Q1 Beats Estimates, Includes Allergan In 2015 Guidance

    IBD
  42. Benzinga's Weekend M&A Chatter

    Benzinga
  43. Report: Mylan Might See Higher Bid From Teva

    Benzinga
  44. Jim Chanos, Kyle Bass Rip Oil And Pharma At SALT 2015

    Benzinga
  45. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD
  46. Leading Stock Mallinckrodt Delivers Strong Results As Base Forms

    IBD
  47. Mylan Q1 Mixed; Abiomed, Mallinckrodt, Zoetis Beat

    IBD
  48. Report Sees 'Cognitive Dissonance' In Mylan's Internal Price ...

    Benzinga
  49. M&A Fever Grips Drugmakers

    IBD
  50. Is The Drug Industry's Wedding Dance Nearly Finished?

    IBD
  51. Gilead's Strong Profit Tops Mixed Drug maker Reports

    IBD
  52. Teva tops as it tries for Mylan

    IBD
  53. Teva, Celgene, Novo Nordisk, Shire Report Q1 Earnings

    IBD
  54. Teva Beats Q1 Estimates, Raises Full-Year Forecast

    Benzinga
  55. Mylan Raises Perrigo Bid, But Perrigo Still Says No

    IBD
  56. Benzinga's M&A Chatter for Monday April 27, 2015

    Benzinga
  57. Mylan Rejects 'Low Quality'

    IBD
  58. Nasdaq Leads Market Lower As Medical Stocks Tumble

    IBD
  59. 4 Drug Giants Reporting Earnings This Week

    IBD
  60. Mylan Rejects Teva Bid After Raising Bid For Perrigo

    IBD
  61. Teva Puts Forth Its Best Bid To Acquire Mylan

    GuruFocus
  62. Perrigo rebuffs Mylan again

    IBD
  63. Mylan 'Raises' Perrigo Bid, But Teva Buzz Builds

    IBD
  64. Benzinga's M&A Chatter for Wednesday April 22, 2015

    Benzinga
  65. Teva Files for Hart-Scott-Rodino Notification Regarding Proposed ...

    Benzinga
  66. Teva Offers $40 Bil For Mylan; Perrigo Rejects Mylan

    IBD
  67. Teva Offers, Perrigo Rejects

    IBD
  68. Stocks End Mixed As Technology Sector Leads

    IBD
  69. Buyers Prop Up Nasdaq; Chipotle Rises Ahead Of Earnings

    IBD
  70. Stocks Mixed, But Palo Alto Hits High On Analyst Nod

    IBD
  71. Teva Bids $40 Billion For Mylan, But May Need More

    IBD
  72. Benzinga's Volume Movers

    Benzinga
  73. Mylan Shares Jump On $40 Billion Bid From Teva Pharmaceutical

    Benzinga
  74. Stocks Slip Into Mixed Trade; DuPont, Harley-Davidson Dive

    IBD
  75. Teva Offers $82 A Share For Mylan; Stocks Rise

    IBD
  76. Stock Futures Mildly Positive; Mylan, Fortinet, Mellanox Surge

    IBD
  77. Teva Pharmaceutical

    IBD
  78. Benzinga's Weekend M&A Chatter

    Benzinga
  79. Mylan

    IBD
  80. Global Worries Sink U.S. Stocks; Apple Breaches Support Level

    IBD
  81. Teva Getting Serious About Mylan Bid, Says Report

    IBD
  82. 8 IBD 50 Stocks Bucking The Market Sell-Off

    IBD
  83. Mylan: There's No Logic In The Teva Merger Rumor

    Benzinga
  84. Stocks Bleed Some More; Nasdaq Breaches Support Level

    IBD
  85. Mylan Scores Final Win In Patent Challenge On Inhalation Drug

    Benzinga
  86. Momenta, Novartis get FDA OK

    IBD
  87. Momenta, Novartis Win FDA Nod For Generic Copaxone

    IBD
  88. Insys Therapeutics Q4 beats

    IBD
  89. Insys Therapeutics Q4 Beat Drives Short-Lived Rally

    IBD
  90. Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic ...

    Benzinga
  91. Stocks Hitting 52-Week Highs

    Benzinga
  92. Morning Market Gainers

    Benzinga
  93. Three Reasons To Let Akorn Fall Into Your Portfolio

    IBD
  94. Generic-Drug Makers Soar, And It's Easy To See Why

    IBD
  95. Stocks Rise In Weak Trade; LinkedIn Jumps After Hours

    IBD
  96. Stocks Close Near Session Highs, But Volume Softens

    IBD
  97. Opko Health And Teva Pharmaceutical Industries Surge Following ...

    Benzinga
  98. Analysts are Bullish on IntelliPharmaceuticals Following Deal ...

    GuruFocus
  99. Biotech Stocks Down Despite Strong Amgen Quarter

    IBD
  100. Deutsche Bank Offers Quick Thoughts On Teva Pharmaceutical's ...

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!